Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bilateral facial weakness with paraesthesia variant of Guillain-Barré syndrome following Vaxzevria COVID-19 vaccine.
Bonifacio GB, Patel D, Cook S, Purcaru E, Couzins M, Domjan J, Ryan S, Alareed A, Tuohy O, Slaght S, Furby J, Allen D, Katifi HA, Kinton L. Bonifacio GB, et al. Among authors: slaght s. J Neurol Neurosurg Psychiatry. 2022 Mar;93(3):341-342. doi: 10.1136/jnnp-2021-327027. Epub 2021 Jul 14. J Neurol Neurosurg Psychiatry. 2022. PMID: 34261746 No abstract available.
The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.
Marson A, Burnside G, Appleton R, Smith D, Leach JP, Sills G, Tudur-Smith C, Plumpton C, Hughes DA, Williamson P, Baker GA, Balabanova S, Taylor C, Brown R, Hindley D, Howell S, Maguire M, Mohanraj R, Smith PE; SANAD II collaborators. Marson A, et al. Lancet. 2021 Apr 10;397(10282):1363-1374. doi: 10.1016/S0140-6736(21)00247-6. Lancet. 2021. PMID: 33838757 Free PMC article. Clinical Trial.
The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.
Marson A, Burnside G, Appleton R, Smith D, Leach JP, Sills G, Tudur-Smith C, Plumpton C, Hughes DA, Williamson P, Baker GA, Balabanova S, Taylor C, Brown R, Hindley D, Howell S, Maguire M, Mohanraj R, Smith PE; SANAD II collaborators. Marson A, et al. Lancet. 2021 Apr 10;397(10282):1375-1386. doi: 10.1016/S0140-6736(21)00246-4. Lancet. 2021. PMID: 33838758 Free PMC article. Clinical Trial.
Glycine receptor autoantibodies disrupt inhibitory neurotransmission.
Crisp SJ, Dixon CL, Jacobson L, Chabrol E, Irani SR, Leite MI, Leschziner G, Slaght SJ, Vincent A, Kullmann DM. Crisp SJ, et al. Among authors: slaght sj. Brain. 2019 Nov 1;142(11):3398-3410. doi: 10.1093/brain/awz297. Brain. 2019. PMID: 31591639 Free PMC article.
Cognitive behavioural therapy for adults with dissociative seizures (CODES): a pragmatic, multicentre, randomised controlled trial.
Goldstein LH, Robinson EJ, Mellers JDC, Stone J, Carson A, Reuber M, Medford N, McCrone P, Murray J, Richardson MP, Pilecka I, Eastwood C, Moore M, Mosweu I, Perdue I, Landau S, Chalder T; CODES study group. Goldstein LH, et al. Lancet Psychiatry. 2020 Jun;7(6):491-505. doi: 10.1016/S2215-0366(20)30128-0. Epub 2020 May 20. Lancet Psychiatry. 2020. PMID: 32445688 Free PMC article. Clinical Trial.
Perampanel for the treatment of epilepsy; Longitudinal actuarial analysis and dose responses based on monthly outcomes.
Stavropoulos I, Louden W, Queally C, Adcock J, Tristram M, Neale M, Moran N, Flores L L, Nashef L, Richardson MP, Bell C, Slaght S, Aram J, Rayner N, Powell R, Mead A, Sen A, Elwes R. Stavropoulos I, et al. Among authors: slaght s. Seizure. 2019 Jul;69:125-132. doi: 10.1016/j.seizure.2019.04.013. Epub 2019 Apr 15. Seizure. 2019. PMID: 31026743 Free article.
19 results